{
  "id": "5a7604de83b0d9ea66000011",
  "type": "summary",
  "question": "What is mechanism of action of galunisertib?",
  "ideal_answer": "Galunisertib is a transforming growth factor-\u03b2 receptor type I kinase inhibitor (TGF-\u03b2RI). It was tested for treatment of solid cancers, including  glioblastoma and neuroblastoma, and liver fibrosis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26309397",
    "http://www.ncbi.nlm.nih.gov/pubmed/27756784",
    "http://www.ncbi.nlm.nih.gov/pubmed/26057634",
    "http://www.ncbi.nlm.nih.gov/pubmed/28230858",
    "http://www.ncbi.nlm.nih.gov/pubmed/27166186",
    "http://www.ncbi.nlm.nih.gov/pubmed/27872101",
    "http://www.ncbi.nlm.nih.gov/pubmed/28691737",
    "http://www.ncbi.nlm.nih.gov/pubmed/28436712",
    "http://www.ncbi.nlm.nih.gov/pubmed/27509307",
    "http://www.ncbi.nlm.nih.gov/pubmed/28481241",
    "http://www.ncbi.nlm.nih.gov/pubmed/26902851",
    "http://www.ncbi.nlm.nih.gov/pubmed/29145888"
  ],
  "snippets": [
    {
      "text": "TGF\u03b2R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27756784",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Galunisertib, an inhibitor of TGF\u03b2R1, was examined for its ability to enhance the efficacy of dinutuximab in combination with human ex vivo activated NK (aNK) cells against neuroblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27756784",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Consequently, blockade of TGF\u03b2 signaling with galunisertib in combination with the anti-GD2 mAb dinutuximab plus adoptively transferred NK cells is a promising tool for the treatment of neuroblastoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27872101",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The small molecule kinase inhibitor galunisertib, targeting the TGF-\u03b2 receptor I (TGF-\u03b2RI), blocks HCC progression in preclinical models and shows promising effects in ongoing clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28230858",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galunisertib, a Transforming growth factor-\u03b2RI (TGF-\u03b2RI) kinase inhibitor, blocks TGF-\u03b2-mediated tumor growth in glioblastoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28481241",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galunisertib, a TGF-\u03b2 receptor type I kinase inhibitor, is a potential candidate for the treatment of liver fibrosis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691737",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A xenograft model provided additional confirmation on combination of TGF-\u03b2 inhibitor (Galunisertib) and autophagy inhibitor (CQ) to better \"turn off\" tumor growth.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145888",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "urther targeting TGF-\u03b2/Smad3 signaling using galunisertib, an inhibitor of the TGF-\u03b2 type I receptor kinase, can attenuate the secretion of miR-21 from glioma cells. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27166186",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Disposition and metabolism of [C]-galunisertib, a TGF-\u03b2RI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28436712",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The combination of galunisertib, a transforming growth factor (TGF)-\u03b2 receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in murine models of glioblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902851",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "1.\u2003The disposition and metabolism of galunisertib (LY2157299 monohydrate, a TGF-\u03b2RI Kinase/ALK5 Inhibitor) was characterized following a single oral dose of 150\u2009mg of [C]-galunisertib (100\u2009\u00b5Ci) to six healthy human subjects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28436712",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26057634",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26309397",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Galunisertib (LY2157299), a selective ATP-mimetic inhibitor of TGF-\u03b2 receptor I (TGF-\u03b2RI), is the only known TGF-\u03b2 pathway inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27509307",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galunisertib (LY2157299) is a selective ATP-mimetic inhibitor of TGF-\u03b2 receptor (T\u03b2R)-I activation currently under clinical investigation in hepatocellular carcinoma (HCC) patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26057634",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galunisertib (LY2157299 monohydrate) is an oral small molecule inhibitor of the TGF-\u03b2 receptor I kinase that specifically downregulates the phosphorylation of SMAD2, abrogating activation of the canonical pathway.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26309397",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galunisertib, a Transforming growth factor-\u03b2RI (TGF-\u03b2RI) kinase inhibitor, blocks TGF-\u03b2-mediated tumor growth in glioblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28481241",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The small molecule kinase inhibitor galunisertib, targeting the TGF-\u03b2 receptor I (TGF-\u03b2RI), blocks HCC progression in preclinical models and shows promising effects in ongoing clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28230858",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galunisertib, a TGF-\u03b2 receptor type I kinase inhibitor, is a potential candidate for the treatment of liver fibrosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691737",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND The combination of galunisertib, a transforming growth factor (TGF)-\u03b2 receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in murine models of glioblastoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902851",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D045504"
  ]
}